DESIGN OF ANTI HIV 1 RIBOZYME DRUG BASED ON 3D STRUCTURE

$7,062P41FY2000RRNIH

Massachusetts Institute Of Technology, Cambridge MA

Investigators

Linked publications & trials

Paper 19728110 Paper 19702261 Paper 19203580 Paper 18306400 Paper 18025040 Paper 17388596 Paper 17323932 Paper 16637644 Paper 16505962 Paper 16331423 Paper 16222556 Paper 16194295 Paper 16041483 Paper 16041480 Paper 16004872 Paper 15814917 Paper 15798152 Paper 15759297 Paper 15610001 Paper 15610000 Paper 15452430 Paper 15379538 Paper 15341733 Paper 15324754 Paper 15253310 Paper 15035634 Paper 14872127 Paper 14733572 Paper 14695294 Paper 14675538 Paper 14664610 Paper 14661955 Paper 14648580 Paper 14599177 Paper 14568517 Paper 14511600 Paper 12939772 Paper 12932461 Paper 12815264 Paper 12815260 Paper 12769594 Paper 12671978 Paper 12660110 Paper 12653563 Paper 12652135 Paper 12615147 Paper 12565053 Paper 12565042 Paper 12490718 Paper 12481032 Paper 12426371 Paper 12419681 Paper 12358535 Paper 12239329 Paper 12207528 Paper 12149447 Paper 12137529 Paper 11960452 Paper 11916398 Paper 11846590 Paper 11841237 Paper 11824761 Paper 11781081 Paper 11749563 Paper 11567583 Paper 11531354 Paper 11504879 Paper 11472128 Paper 11472123 Paper 11456650 Paper 11425548 Paper 11352724 Paper 11258891 Paper 11222853 Paper 10968966 Paper 10889021 Paper 10856302 Paper 10820006 Paper 10783283 Paper 10630997 Paper 10617445

Abstract

Among the various therapeutic agents currently being developed for the treatment of AIDS pathogenesis, catalytically active RNAs targeted to RNA genes and gene products of HIV-1 and other associated opportunistic pathogens are one of the most promising approaches. This project addresses the rational design of a catalytically efficient, nuclease resistant ribozyme targeting a particular, single site in the HIV-1 RNA.

View original record on NIH RePORTER →